Pulmonary endothelin-1 clearance in human pulmonary arterial hypertension

Chest

Volumn 128, Issue 6 SUPPL., 2005, Pages

  Langleben, David ^a   Dupuis, J ^a   Hirsch, A ^a   Giovinazzo, M ^a   Langleben, I ^a   Khoury, J ^a   Ruel, N ^a   Caron, A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN B RECEPTOR; IODINE 125;

CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; ENDOTHELIUM CELL; HUMAN; LUNG CIRCULATION; LUNG PERFUSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

ENDOTHELIN-1; HUMANS; HYPERTENSION, PULMONARY; LUNG;

EID: 30144440671     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.6_suppl.622S     Document Type: Conference Paper

References (46)

1. D'Alonzo GE Barst RJ Ayres SM Survival in patients with primary pulmonary hypertension: results from a national prospective registry Ann Intern Med 115 1991 343 349
2. Sitbon O Humbert M Nunes H Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788
3. Farber HW Loscalzo J Mechanisms of disease: pulmonary arterial hypertension N Engl J Med 351 2004 1655 1665
4. Humbert M Sitbon O Simonneau G Treatment of pulmonary arterial hypertension N Engl J Med 351 2004 1425 1436
5. Mc Laughlin VV Shillington A Rich S Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 2002 1477 1482
6. Mc Goon M Gutterman D Steen V Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest 126(suppl) 2004 14S 34S
7. Humbert M Chaouat A Bertocchi M ItinerAIR-HTAP: a French national prospective registry og pulmonary arterial hypertension [abstract] Am J Respir Crit Care Med 169 2004 A169
8. Grunig E Janssen B Mereles D Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene Circulation 102 2000 1145 1150
9. Newman JH Trembath RC Morse JA Genetic basis of pulmonary arterial hypertension: Current understanding and future directions J Am Coll Cardiol 43 2004 S33 S39
10. Simonneau G Galie N Rubin LJ Clinical classification of pulmonary hypertension J Am Coll Cardiol 43 2004 5S 12S
11. Doyle RL Mc Crory D Channick RN Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest 126(suppl) 2004 63S 71S
12. Filipek MS Gosselin MV Multidetector pulmonary CT angiography: advances in the evaluation of pulmonary arterial diseases Semin Ultrasound CT MR 25 2004 83 98
13. Mandel J Mark EJ Hales CA Pulmonary veno-occlusive disease Am J Respir Crit Care Med 162 2000 1964 1973
14. Humbert M Maitre S Capron F Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis Am J Respir Crit Care Med 157 1998 1681 1685
15. Nicod P Moser KM Primary pulmonary hypertension: the risk and benefit of lung biopsy Circulation 80 1989 1486 1488
16. Resten A Maitre S Humbert M Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease AJR Am J Roentgenol 183 2004 65 70
17. Rabiller A Humbert M Sitbon O Bronchoalveolar lavage as a diagnostic tool in pulmonary hypertension: occult alveolar hemorrhage is a common feature of pulmonary veno-occlusive disease [abstract] Am J Respir Crit Care Med 167 2003 A276
18. Barbera JA Peinado VI Santos S Pulmonary hypertension in chronic obstructive pulmonary disease Eur Respir J 21 2003 892 905
19. Eddahibi S Chaouat A Morrell N Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease Circulation 108 2003 1839 1844
20. Roberts KE Mc Elroy JJ Wong WP BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease Eur Respir J 24 2004 371 374
21. Humbert M Deng Z Simonneau G BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives Eur Respir J 20 2002 518 523
22. Mc Laughlin VV Presberg KW Doyle RL Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest 126(suppl) 2004 78S 92S
23. Badesch DB Abman SH Ahearn GS Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest 126(suppl) 2004 35S 62S
24. Suleman N Frost AE Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension Chest 126 2004 808 815
25. Sitbon O Humbert M Ioos V Transition from intravenous epoprostenol to oral bosentan in pulmonary arterial hypertension [abstract] Am J Respir Crit Care Med 169 2004 A176
26. Castelain V Chemla D Humbert M Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension Am J Respir Crit Care Med 165 2002 338 340
27. Enright PL Sherrill DL Reference equations for the six-minute walk in healthy adults Am J Respir Crit Care Med 158 1998 1384 1387
28. Frost A Langleben D Hill NS 6MW as an efficacy endpoint in PAH trials: demonstration of a ceiling effect [abstract] Am J Respir Crit Care Med 169 2004 A176
29. Sitbon O Humbert M Jais X Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension Circulation 111 2005 3105 3111
30. Sastry BK Narasimhan C Reddy NK Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study J Am Coll Cardiol 43 2004 1149 1153
31. Mc Laughlin VV Sitbon O Badesch DB Survival with first-line bosentan in patients with primary pulmonary hypertension Eur Respir J 25 2005 244 249
32. Hoeper MM Schwarze M Ehlerding S Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue N Engl J Med 342 2000 1866 1870
33. Sitbon O Badesch DB Channick RN Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study Chest 124 2003 247 254
34. Langleben D Hirsch AM Shalit E Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study Chest 126 2004 1377 1381
35. Barst RJ Mc Goon M Mc Laughlin V Beraprost therapy for pulmonary arterial hypertension J Am Coll Cardiol 41 2003 2119 2125
36. Olschewski H Simonneau G Galie N Inhaled iloprost for severe pulmonary hypertension N Engl J Med 347 2002 322 329
37. Nagaya N Uematsu M Okano Y Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension J Am Coll Cardiol 34 1999 1188 1192
38. Barst RJ Rubin LJ Long WA A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group N Engl J Med 334 1996 296 302
39. Ghofrani HA Rose F Schermuly RT Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension J Am Coll Cardiol 42 2003 158 164
40. Stiebellehner L Petkov V Vonbank K Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension Chest 123 2003 1293 1295
41. Hoeper MM Taha N Bekjarova A Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids Eur Respir J 22 2003 330 334
42. Humbert M Barst RJ Robbins IM Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Eur Respir J 24 2004 353 359
43. Petkov V Mosgoeller W Ziesche R Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension J Clin Invest 111 2003 1339 1346
44. Cowan KN Jones PL Rabinovitch M Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease J Clin Invest 105 2000 21 34
45. Marcos E Adnot S Pham MH Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension Am J Respir Crit Care Med 168 2003 487 493
46. Nagaya N Kyotani S Uematsu M Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension Circulation 109 2004 351 356